One of the lung cancer surgeons I work closely with sent me and a couple of the radiation oncologists at my center a report that just came out from a...
A few months ago, I had a patient in my clinic who is a lifelong never-smoker with an adenocarcinoma. I had her tumor checked for molecular markers...
Drs. Bob Doebele, Ross Camidge, and their colleagues at the University of Colorado just published an interesting and clinically relevant paper in...
Thanks (and congratulations) to GRACE member Craig, who highlighted the just-published report that is the first to characterize the frequency and...
Several weeks ago we did a webinar, co-sponsored with LUNGevity Foundation, with Dr. Mark Millard, pulmonologist at Baylor University in Dallas, TX...
A post on About.com makes the case that screening the higher risk population of just those people 55-75 with a significant smoking history, as was done in the influential Na
It has been a long time since we've talked about Nexavar (sorafenib), an oral anti-angiogenic targeted therapy that works as a "multi-kinase inhibitor" and is FDA approved in some other cancers such as renal cell and liver cancer. In lung cancer, some small, early research done years ago revealed that it has activity in at least a minority of patients with advanced NSCLC.
It's been over two years since I reported the details from a positive trial for Abraxane (albumin-bound paclitaxel) as a weekly treatment combined with carboplatin and compared with standard "solvent-based" Taxol (paclitaxel) along with carboplatin. While positive for showing a 8% difference in response rate, which was the primary endpoint, it didn't show a significant difference in overall survival (OS), as revealed in the
One of the more promising agents for advanced NSCLC in the last few years has been the oral Met inhibitor tivantinib, also known as ARQ-197.
We've covered a wide range of topics in our "ASCO 2012 Lung Cancer Highlights" podcast series over the last few weeks. This webinar and the podcasts from it featured Drs.
GRACE in partnership with LUNGevity Foundation are thrilled to offer our next webinar on Wednesday, October 24th, at 6:30 PM Eastern/3:30 PM Pacific, with the renowned Dr. David Harpole, Thoracic Surgeon and Professor of Surgery at Duke University Medical Center. Dr.
Just last week I reviewed the favorable results in a randomized phase II clinical trial with the novel vascular-targeting immunotherapy bavituximab, which was associated with an approximate doubling of median overall survival when added to Taxotere (docetaxel) and compared with Taxotere alone, along with a much more modest improvement in response rate and progression-free survival.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
